Resources
About Us
China Microarray Market Size, Share, Forecast, & Trend Analysis by Product (Consumables [Microarray Kits {DNA (cDNA, Oligo), Protein}], Instruments, Software, Services), Application (Drug Discovery, Research, Diagnostics), End User— Forecast to 2031
Report ID: MRHC - 1041321 Pages: 109 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 Hours Download Free Sample ReportThe growth of the China microarray market is driven by expanding research applications of microarrays, increasing genomics and proteomics research, the rising prevalence of cancers and genetic disorders, and increasing R&D investments by the pharma and biotech stakeholders. However, the market growth is restrained by the expensive nature of microarrays over other genetic testing approaches and the increasing adoption of next-generation sequencing technologies. Moreover, the growing adoption of personalized medicines is expected to generate growth opportunities for market stakeholders. The low sensitivity and correctness of microarrays pose a challenge to the growth of the market.
Microarray technology involves the binding of an array of millions of nucleic acid fragments to a solid surface, which is generally referred to as a chip. A DNA or RNA sample is then added to the chip in order to initiate complementary base pairing when the immobilized fragments on the chip produce light through fluorescence that is detected using a specialized device. Microarray technology allows genomic analysis without sequencing and greatly reduces the cost of performing experiments across the fields of biology and biomedicine. Initially, microarray technology was only used to measure gene expression or quantify certain small molecules. However, the advancements in microarray technology are making it a fast and reliable solution for various applications, such as biomarkers and drug discovery.
Research applications of microarray include clinical trials and drug discoveries for various purposes, such as gene expression, detection of DNA sequences, studying gene mutations, and the presence of certain biomarkers. It can be used as a genomic tool to study and compare different features of the genome based on different diseases and conditions. Due to the study of genomics and data acquired using the technology, population-based studies can also be carried out.
Click here to: Get Free Sample Pages of this Report
Cancer is a major cause of death and a prominent obstacle to improving life expectancy around the world. According to GLOBOCAN, in China, the number of new cancer cases in 2022 was 4.8 million, which is expected to reach 7.1 million by 2045. Thus, the increasing number of cancer cases is expected to boost the adoption of microarrays in clinical settings. Microarray applications in oncology research range from basic drug discovery and translational research to patient testing, clinical trials, and population studies.
Apart from cancer, China also shares a significant burden of rare genetic disorders across the world. Congenital disabilities in children have been a major factor contributing to the country’s disease burden. The government currently subsidizes screening of 12 types of congenital disabilities. As per a report published in the International Journal of Environmental Research and Public Health in July 2022, China has a high prevalence of congenital disabilities of nearly 5.6%, and it is estimated that nearly 800,000 to 1,200,000 people children every year are found with malformations, which includes more than 2,500,000 malformation cases.
For this, certain chromosomal diagnostic arrays are being used to test individuals for unexplained developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASDs), or multiple congenital anomalies (MCA).
Microarray is a laboratory technique used in the high-throughput analysis of many biological molecules, such as DNA, RNA, proteins, or antibodies, in a single experiment. Microarrays play an important role in the detection of Biological Warfare Agents (BWAs) which are microorganisms or toxins produced by the organisms and are dispersed by people to spread diseases in a community. Microarrays can be used for the fast, sensitive, and simultaneous identification of these agents. The current application of microarrays is the use of a Bead Array Counter (BARC), which is a multi-analyte biosensor that uses DNA hybridization, magnetic microbeads, and giant magnetoresistive (GMR) sensors to identify and detect BWAs.
Furthermore, microarrays play an important role in forensics to identify suspects and missing people by analyzing evidence to analyze evidence from crime scenes, such as degraded samples, determining geographic origins, and analyzing mixtures that can be helpful during the investigation. The growing demand for DNA-based evidence in forensics is a notable trend that is expected to have a positive impact on the adoption of microarray for forensic applications.
There has been a growing trend of 3D printing in the healthcare sector. One such use of 3D printing is microarray printing. Microarray bioprinting refers to printing cells that are encapsulated in hydrogels and use automated liquid dispensing tools or robots such as microarray spotters. These spotters are used to make microarray chips. This technology deposits cDNA probes onto a microscope slide or any other substrate. It has various advantages such as physiologically relevant cells grown in 3D, miniaturization of cell-based assays, reduced use of raw materials life primary human cells obtained from patients, and ultrahigh-throughput capability of testing cell culture conditions.
One of the major applications that uses 3D printed microarrays is drug delivery systems. The transdermal route is one of the most common means of drug delivery that is minimally invasive. The products used for this are microneedles or microarray patches (MAPs), which painlessly puncture the skin of the patient and access the epidermal/dermal layer. In 2022, the DeSimone Laboratory of the University of Virginia School of Medicine (U.S.) developed a high-resolution continuous liquid interface production (CLIP) 3D printing technology, which uses light and oxygen to enable a continuous, noncontact polymerization dead zone at the build surface, which allows for the rapid production of MAPs with precise and tunable geometries.
In August 2024, CapitalBio Technology Co., Ltd. (China) launched the Chromosome Microarray (CMA) Detection 2.0 microarray chips to investigate chromosomal factors that cause miscarriages and abnormalities.
In August 2023, Thermo Fisher Scientific, Inc. (U.S.) launched a chromosomal microarray to improve cytogenic research lab productivity, efficiency, and profitability. This is in response to the growing demand for laboratory services and the ongoing shortage of laboratory professionals.
Such developments in microarray technology provide several benefits, such as personalized services for patients according to their condition, rapid and accurate results, and high-quality data. These advancements can be applied in various aspects of the research and diagnostic field, such as clinical trials, research studies, biomarker discovery, and diagnosis and treatment of diseases, supporting market growth.
Based on product, the China microarray market is segmented into instruments, consumables, software, and services. In 2024, the consumables segment is expected to account for the largest share of 62.6% of the China microarray market. The substantial market share of this segment is due to the increasing incidence of cancer, wide application areas of microarray technology, rising funding for genomic R&D, and growing research for personalized medicine.
Furthermore, the consumables segment is slated to register the highest CAGR of 9.2% during the forecast period. The increased volume of testing for chronic diseases and the rising awareness among the general population about testing and disease awareness drive this segment's growth.
Based on application, the China microarray market is segmented into drug discovery & development, research applications, diagnostics, and other applications. In 2024, the drug discovery & development segment is expected to account for the largest share of 51.7% of the China microarray market. The large market share is due to the growing public and private investments in pharma and biotech R&D and initiatives by the pharmaceutical and biotechnology companies to expand their research capabilities by opening new research centers and launches of new and innovative microarray technologies.
Moreover, the research applications segment is expected to record the highest CAGR of 9.2% during the forecast period. The high sensitivity of microarray technologies, low sample volume requirements, and cost-effectiveness drive this segment's growth.
Based on end user, the China microarray market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), research and academic institutes, hospitals & diagnostic laboratories, and other end users, which includes veterinary clinics, the agricultural industry, and forensic laboratories. In 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market. This segment's substantial market share is due to high pharmaceutical R&D expenditure, rising demand for new drug discovery & development, increasing funding, grants, and investments for genomic research, and growing focus on increasing overall productivity. The rising demand for drug discovery coupled with the rising R&D expenditure will increase the demand for techniques such as microarray technology that offer accurate results and provide better and vast information.
Moreover, the contract research organizations (CROs) segment is projected to record the highest CAGR during the forecast period.
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants over the past three to four years. The key players profiled in China microarray market report are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
China Microarray Market Industry Overview: Latest Developments from Key Industry Players
In January 2024, Thermo Fisher Scientific, Inc. (U.S.) launched the Axiom PangenomiX Array, which offers optimal genetic coverage for population-scale disease studies and pharmacogenomics research.
In January 2024, Bristol Myers Squibb (BMS) (U.S.), Glaxo Smith Kline plc (GSK) (U.K.), and Novo Nordisk (Denmark) joined the Alliance for Genomic Discovery headed by Illumina to co-fund the whole-genome sequencing (WGS) of 250,000 DNA samples. The alliance also aims to gain access to the resulting data for use in drug discovery and therapeutic development.
In September 2022, Thermo Fisher Scientific, Inc. (U.S.) partnered with the Taiwan Precision Medicine Initiative (TPMI) to conduct a large-scale predictive genomics study and genotype 1 million people in Taiwan.
Particulars |
Details |
Page No |
109 |
Format |
|
Forecast Period |
2024-2031 |
Base Year |
2023 |
CAGR |
8.4% |
Market Size (Value) |
$910.4 million by 2031 |
Segments Covered |
By Product
By Application
By End User
|
Countries Covered |
China |
Key Companies |
Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.) |
The China microarray market report covers qualitative analysis and market sizing based on product and end user. It analyzes various segments of the China microarray market at the country level and offers insights on factors impacting market growth, factor analysis, case studies, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The China microarray market is projected to reach $910.4 million by 2031, at a CAGR of 8.4% during the forecast period.
The consumables segment is expected to account for the largest share of the China microarray market in 2024. Factors such as the high burden of diseases, the high adoption of microarray kits, and the presence of initiatives supporting disease diagnosis support this segment's largest share.
Based on the application, the research application segment is projected to create more traction.
Based on end user, the contract research organizations segment is projected to register the highest growth during the forecast period.
The expanding research applications of microarrays, increasing genomics and proteomics research activities, the rising prevalence of cancers and genetic disorders, and growing R&D investments by the pharmaceutical and biotechnology sectors are factors supporting the growth of this market. Furthermore, advancements in microarray technology and the growing adoption of personalized medicine are anticipated to offer significant growth opportunities for companies operating in this market.
Published Date: Sep-2024
Published Date: Feb-2024
Published Date: Mar-2019
Published Date: Jan-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates